| abstract |
A solid pro-apoptotic dispersion comprises, in essentially non-crystalline form, a compound of the formula I protein inhibitor of the Bcl-2 family as defined in the present application, dispersed in a solid matrix comprising (a) a vehicle pharmaceutically acceptable water-soluble polymer and (b) a pharmaceutically acceptable surfactant. A process for preparing said solid dispersion comprises dissolving the compound, the polymeric vehicle and the surface active agent in an appropriate solvent, and removing the solvent to provide a solid matrix comprising the polymeric vehicle and the surface active agent and having the dispersed compound in form. essentially not crystalline in it. The solid dispersion is suitable for oral administration to an individual in need thereof for the treatment of a disease characterized by overexpression of one or more proteins of the anti-apoptotic Bcl-2 family, for example cancer. |